Cargando…
Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial
Losartan has become a hot spot in the treatment of non-alcoholic fatty liver disease (NAFLD) among angiotensin receptor blocker drugs. We sought to conduct a systematic examination and meta-analysis to examine the effects of losartan on patients with NAFLD. We searched for potentially randomized con...
Autores principales: | Meng, Chang, Song, Zejun, Zhang, Lingnan, Geng, Yu, Sun, Jing, Miao, Guobin, Liu, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031500/ https://www.ncbi.nlm.nih.gov/pubmed/36970603 http://dx.doi.org/10.1515/biol-2022-0583 |
Ejemplares similares
-
Randomized placebo‐controlled trial of losartan for pediatric NAFLD
por: Vos, Miriam B., et al.
Publicado: (2022) -
Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1α in a Murine Model of NAFLD
por: Wang, Cheng-Hui, et al.
Publicado: (2021) -
Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial
por: Zhang, Shuyang, et al.
Publicado: (2023) -
Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials
por: Elbadawi, Ayman, et al.
Publicado: (2019) -
Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial
por: Mao, Wei, et al.
Publicado: (2021)